![John Volpone](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: 1 Mio $ am 31.05.2026
John Volpone is currently Chief Operating Officer at X4 Pharmaceuticals, Inc. Formerly, Mr. Volpone was Director-Business Development at ZymoGenetics, Inc. and Senior Vice President-Strategic Operations at.
CTI BioPharma Corp.
Education includes an undergraduate degree from the University of Washington and an MBA from Seattle University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
X4 PHARMACEUTICALS, INC. 0,31 % | 29.10.2025 | 289.881 ( 0,31 % ) | 1 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| X4 PHARMACEUTICALS, INC. | Geschäftsführer | 16.09.2025 |
| Unternehmen | Position | Ende |
|---|---|---|
| CTI BIOPHARMA CORP. | Personalreferent | 01.10.2023 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 5 |
|---|---|
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology Engages in acquisition, development and commercialization of novel targeted therapies for blood-related cancers | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Health Technology |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Seattle University
 Seattle University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
X4 Pharmaceuticals, Inc.
 X4 Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
